A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis (NCT06736990)
A Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.
Who can join: Review the eligibility criteria below.
Location: Keck School of Medicine at USC — Los Angeles, California
Age range: 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (54 Sites)
Showing the first 25 of 54 sites.
- Keck School of Medicine at USC — Los Angeles, California
- National Jewish Health — Denver, Colorado
- Y & L Advance Health Care, Inc. d/b/a Elite Clinical Research — Miami, Florida
- University of Kansas Medical Center — Kansas City, Kansas
- Pulmonix, LLC — Greensboro, North Carolina
- Southeastern Research Center — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Temple University Hospital — Philadelphia, Pennsylvania
- University of Utah Health — Salt Lake City, Utah
- Aarhus University Hospital — Aarhus,
- Rigshospitalet — Copenhagen,
- Odense University Hospital — Odense,
- AP-HP Hopital Avicenne — Bobigny,
- AP-HP Hopital Europeen Georges Pompidou — Paris,
- CHU Rennes - Hopital Pontchaillou — Rennes,
- CHU de Toulouse - Hopital Larrey — Toulouse,
- CHRU de Tours - Hôpital Bretonneau — Tours,
- Azienda Ospedale - Università Padova — Padova, PD
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore — Roma, RM
- Azienda Ospedaliero Universitaria Senese — Siena, SI
- Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale di Cattinara — Trieste, TS
- Azienda Ospedaliero-Universitaria di Modena — Modena,
- AORN - Ospedali dei Colli - Ospedale V. Monaldi — Naples,
- Istituto Clinico Humanitas - Pneumologia 1 — Rozzano,
- Erasmus MC — Rotterdam, South Holland
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Fibrosis
- Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) — Quilmes, Buenos Aires
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
- LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Birmingham, Alabama
- Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis — Seattle, Washington
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Camperdown, New South Wales
Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.